Guidelines and Best Practices for the Use of Targeted Maximum Likelihood and Machine Learning When Estimating Causal Effects of Exposures on Time-To-Event Outcomes.

Journal: Statistics in medicine
PMID:

Abstract

Targeted maximum likelihood estimation (TMLE) is an increasingly popular framework for the estimation of causal effects. It requires modeling both the exposure and outcome but is doubly robust in the sense that it is valid if at least one of these models is correctly specified. In addition, TMLE allows for flexible modeling of both the exposure and outcome with machine learning methods. This provides better control for measured confounders since the model specification automatically adapts to the data, instead of needing to be specified by the analyst a priori. Despite these methodological advantages, TMLE remains less popular than alternatives in part because of its less accessible theory and implementation. While some tutorials have been proposed, none address the case of a time-to-event outcome. This tutorial provides a detailed step-by-step explanation of the implementation of TMLE for estimating the effect of a point binary or multilevel exposure on a time-to-event outcome, modeled as counterfactual survival curves and causal hazard ratios. The tutorial also provides guidelines on how best to use TMLE in practice, including aspects related to study design, choice of covariates, controlling biases and use of machine learning. R-code is provided to illustrate each step using simulated data ( https://github.com/detal9/SurvTMLE). To facilitate implementation, a general R function implementing TMLE with options to use machine learning is also provided. The method is illustrated in a real-data analysis concerning the effectiveness of statins for the prevention of a first cardiovascular disease among older adults in Québec, Canada, between 2013 and 2018.

Authors

  • Denis Talbot
    Faculty of Medicine, Department of Social and Preventive Medicine, Université Laval, Quebec, QC, Canada.
  • Awa Diop
    Département de Médecine Sociale et Préventive, Université Laval, Québec, Canada.
  • Miceline Mésidor
    Département de Médecine Sociale et Préventive, Université Laval, Québec, Canada.
  • Yohann Chiu
    Faculty of Pharmacy, Université Laval, Quebec, QC, Canada.
  • Caroline Sirois
    Faculty of Pharmacy, Université Laval, Quebec, QC, Canada. caroline.sirois@pha.ulaval.ca.
  • Andrew J Spieker
    Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Antoine Pariente
    INSERM, BPH, U1219, Team Pharmacoepidemiology, Univ. Bordeaux, Bordeaux, France.
  • Pernelle Noize
    University of Bordeaux, Bordeaux, France.
  • Marc Simard
    Quebec National Institute of Public Health, Quebec, QC, Canada.
  • Miguel Angel Luque Fernandez
    Inequalities in Cancer Outcomes Network, London School of Hygiene and Tropical Medicine, London, UK.
  • Michael Schomaker
    Ludwig-Maximilans-Universität, München, Germany.
  • Kenji Fujita
    Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.
  • Danijela Gnjidic
    School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Camperdown, Sydney, Australia.
  • Mireille E Schnitzer